Search Results for "Alnylam"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
APOLLO Post-Hoc Analysis by Baseline Polyneuropathy Severity
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
Long-term Assessment of Patients with AHP and AIP who were Not Attack-Free after 6-Months of Givosiran Treatment: A Post Hoc Subgroup Analysis of the Phase 3 ENVISION Study
An infographic depicting a post-hoc analysis of the ENVISION phase 3 study to understand the long-term clinical outcomes of patients who were not attack free after 6-months of givosiran treatment.
An infographic depicting a post-hoc analysis of the ENVISION phase 3 study to understand the long-term clinical outcomes of patients who were not attack free after 6-months of givosiran treatment.
